Werewolf Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-41.58	-37.37	-53.81	-201.93	-28.22	-18.23
Depreciation & Amortization	3.42	3.34	2.51	0.74	0.78	0.46
Share-Based Compensation	8.21	8.01	7.4	4.1	0.63	0.56
Other Operating Activities	-8.06	-6.59	3.3	2.28	-4.99	-0.32
Operating Cash Flow	-38.01	-32.61	-40.6	-42.88	-18.62	-9.54
Capital Expenditures	-0.71	-0.77	-3.61	-0.5	-0.56	-0.27
Investing Cash Flow	-0.71	-0.77	-3.61	-0.5	-0.56	-0.27
Share Issuance / Repurchase	30.07	18.43	15.99	109.43	-0.16	-0.19
Debt Issued / Paid	0	40	-0.09	0	0	0
Other Financing Activities	-	-	-	-	94.02	22.1
Financing Cash Flow	30.07	58.43	15.91	109.43	93.86	21.91
Net Cash Flow	-8.66	25.05	-28.3	66.05	74.67	12.1
Free Cash Flow	-38.72	-33.38	-44.21	-43.37	-19.18	-9.81
Free Cash Flow Margin	-238.72%	-167.38%	-269.54%	-	-	-
Free Cash Flow Per Share	-0.93	-0.94	-1.53	-2.35	-19.09	-15.33

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).